Biosense Webster launches Carto 3 MEM version for mapping arrhythmias


On 13 August, Biosense Webster announced the launch of the new Carto 3 Multi-Electrode Mapping (MEM) version in the United States.

The Carto 3 MEM version is the latest advancement on the Carto 3 System platform. According to a company release, the new Carto 3 MEM version provides a fast method for mapping and diagnosing arrhythmias, while using sensor-based MEM-enabled catheters to maintain a high degree of anatomical accuracy. The new Pentaray Nav Catheter is equipped with the electromagnetic sensor, allowing for accurate visualisation of electrode position on the Carto 3 System and higher resolution signals.

“Multi-electrode mapping represents a significant advancement in mapping technology, allowing physicians to acquire multiple mapping points simultaneously with a high level of detail and CARTO 3 System accuracy,” said Vivek Reddy, Mount Sinai School of Medicine, New York, USA. “Combined with the new Pentaray Nav Catheter, you can reduce the number of required catheter maneuvers to quickly diagnose any arrhythmia. This further supports the safety, effectiveness and efficiency of cardiac ablation procedures for patients.”